0
2020
Polycystic Ovarian Syndrome Treatment Market

Polycystic Ovarian Syndrome Treatment Market

by Drug Class (Insulin Sensitizing Agent, Oral Contraceptive, Antiandrogens, Anti-Obesity Drugs, and Others), and Distribution Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2019-2026

Report Code: A05949
Pages: 217
Jan 2020 | 9559 Views
Author(s) : Sayali S , Onkar S
Tables: 90
Charts: 56
  • Formats*:

  • Single User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Polycystic Ovarian Syndrome Treatment Market

Request Now !

Polycystic Ovarian Syndrome Treatment Market Outlook – 2026

The global polycystic ovarian syndrome treatment market size was valued at $2,902 million in 2018, and is projected to reach $4,184 million by 2026, registering a CAGR of 4.7% from 2019 to 2026. 

Polycystic ovary syndrome or PCOS is a hormonal disorder that is common among women of childbearing age. PCOS causes infrequent or prolonged menstrual cycle or excess male hormone levels. Presently, there is no cure for PCOS, however, various medications are used to regulate menstrual cycle and to manage symptoms of PCOS. 

Polycystic Ovarian Syndrome Treatment Market

Increase in prevalence of PCOS, rise in awareness among patient population with increase in adoption of combination therapy drives the polycystic ovarian syndrome treatment market growth. In addition, easy accessibility to PCOS therapeutics, rise in demand for PCOS medications, and technological advancements for detection of PCOS influence the market growth. However, lack of approved therapeutics, and unknown etiology and pathophysiology of PCOS is anticipated to hamper the market growth. Furthermore, untapped potential offered by developing economies present lucrative opportunities for the growth of the polycystic ovarian syndrome treatment market during the forecast period. However, lack of specific treatment for PCOS disorder is expected to restrain the growth of the market. The rise in prevalence of PCOS is expected to augment the demand for PCOS treatment medications. For instance, Centers for Disease Control and Prevention estimated that PCOS is one of the most common causes of female infertility, affecting 6 to 12% (as many as 5 million) of the American women of reproductive age. The number of PCOS patients is increasing due to the growing incidences of co-morbid conditions such as diabetes and obesity.

Polycystic Ovarian Syndrome Treatment Market Segmentation  

The global polycystic ovarian syndrome treatment market is segmented on the basis of drug class, distribution channel, and region. Based on drug class, it is classified as insulin sensitizing agent, oral contraceptive, antiandrogens, anti-obesity drugs, and others. According to distribution channel, it is categorized as hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).   

Segment Review 

By drug class, the market is categorized into insulin sensitizing agent, oral contraceptive, antiandrogens, anti-obesity drugs, and others. Presently, the insulin sensitizing agent segment is the major revenue contributing segment in 2018 and is estimated to show a significant market growth during the forecast period due to higher adoption of insulin sensitizing agents as the first line treatment for the management of PCOS.

Polycystic Ovarian Syndrome Treatment Market
By Drug Class

Your browser does not support the canvas element.

Oral Contraceptive is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

According to distribution channel, the polycystic ovarian syndrome treatment market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The online providers segment is anticipated to depict a significant growth during the forecast period, due to rise in preference for online purchasing of drugs over the traditional methods, increase in awareness of online providers, and rise in number of internet users.

Polycystic Ovarian Syndrome Treatment Market
By Distribution Channel

Your browser does not support the canvas element.

Drug Store and Retail Pharmacy holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Snapshot of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market  

Asia-Pacific presents lucrative opportunities for the key players operating in the polycystic ovarian syndrome treatment market, owing to the growth in awareness about polycystic ovarian syndrome treatment, rise in adoption of polycystic ovarian syndrome treatment products will drive the market growth. Moreover, improvement in healthcare infrastructure, rise in number of target population, developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare further contributes to the market growth. In addition, factors such as surge in focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the market, high population base, and high disposable incomes are also expected to drive the growth of the polycystic ovarian syndrome treatment market in Asia-Pacific. 

Polycystic Ovarian Syndrome Treatment Market
By Geography

2026
North America 
Europe
Asia-Pacific
LAMEA

Asia-Pacific region would exhibit the highest CAGR of 5.4% during 2019-2026.

Get more information on this report : Request Sample Pages

The key players profiled in this report include Allergan plc., AstraZeneca plc., Bayer AG, Bristol-Myers Squibb Company, Johnson and Johnson, Mylan N.V., Novartis AG, Pfizer Inc., SANOFI, and Teva Pharmaceutical Industries. 

Key Benefits for Stakeholders:

  • The study provides an in-depth analysis along with the current polycystic ovarian syndrome treatment market trends and future estimations to elucidate the imminent investment pockets.
  • It offers polycystic ovarian syndrome treatment market analysis from 2018 to 2026, which is expected to enable stakeholders to capitalize the prevailing opportunities in the market.
  • A comprehensive analysis of four major regions is provided to determine the prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global polycystic ovarian syndrome treatment market growth.

Polycystic Ovarian Syndrome Treatment Market Report Highlights

Aspects Details
By Drug Class
  • Insulin Sensitizing Agent
  • Oral Contraceptive
  • Antiandrogens
  • Anti-Obesity Drugs
  • Others
BY END USER
  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online pharmacies
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Allergan plc, AstraZeneca plc, Bayer AG., Bristol-Myers Squibb Company, Johnson and Johnson, Mylan N.V, Novartis AG, Pfizer Inc., SANOFI, Teva Pharmaceutical Industries
 

Loading Table Of Content...


 
 

Though there is no proper cure for PCOS but current polycystic ovarian syndrome treatment medications relieve patients from its symptoms and improves the quality of life. Different forms of drugs such as insulin sensitizing agent, oral contraceptive, antiandrogens, anti-obesity drugs, and others are used in management of PCOS. 

Increase in prevalence of PCOS, adoption of sedentary lifestyle, surge in level of stress and unhealthy diet, and rise in awareness regarding polycystic ovarian syndrome treatment significantly boosts the growth of the market. However, there is no approved drug for treatment of PCOS, which is anticipated to hinders the market growth.

North America is expected to remain dominant during the forecast period due to higher adoption of polycystic ovarian syndrome treatment products with increase in number target population. Early detection with higher health awareness among the general population drives the market growth in this region. In addition, Asia-Pacific is expected to offer lucrative opportunities for the key players during the forecast period, due to growing prevalence of PCOS along with rise in awareness of polycystic ovarian syndrome treatment products.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The market value of global Polycystic Ovarian Syndrome Treatment market was $2,902.4 million in 2018.

A. The forecast period is from 2019 to 2026.

A. The market value of global Polycystic Ovarian Syndrome Treatment market in 2019 is $3,040.8 million.

A. The adoption of Polycystic Ovarian Syndrome medication is expected to due to increase in prevalence of PCOS, rise in awareness among the patient population with increase in popularity of combination therapy drives the market growth. In addition, easy accessibility to PCOS therapeutics, rise in demand for PCOS medication, and technological advancement for detection of PCOS influence the market growth. However, lack of approved therapeutics, and unknown etiology and pathophysiology of PCOS may hamper the market growth

A. The base year calculated in the report is 2018.

A. Yes, Allergan is profiled in the report.

A. Emerging countries of Asia-Pacific region are growing at a growth% of 6.3%. Japan, China, Australia, India, South Korea are expected grow at a CAGR of 6.2%, 7.4%, 5.5%, 7.0%, 5.8%, respectively.

A. The North America market held a major share in the Polycystic Ovarian Syndrome Treatment market in 2018 and is expected to continue the trend in the forecasting period. This is attributed to higher prevalence of PCOS, higher healthcare awareness, presence of well-developed healthcare infrastructure along with early detection of the disease, presence of trained medical professionals, and easy accessibility to the therapeutics are majorly driving the market growth in North America

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
RELATED TAGS

Purchase Full Report of
Polycystic Ovarian Syndrome Treatment Market

Start reading instantly.
This Report and over 19,660+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Jan 2021 - Jan 2022)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jan 2021 - Jan 2022)
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jan 2021 - Jan 2022)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jan 2021 - Jan 2022)
  • Enterprise
    License/PDF

  • $10,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jan 2021 - Jan 2022)
  • Library
    Membership

  • $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers